TREATMENT OF HYPERCALCEMIC/HYPERCALCIURIC PATIENTS W/ CHLOROQUINE,HYD

用氯喹治疗高钙血症/高钙尿症患者

• 批准号: 6264903
• 负责人: John S Adams
• 金额: $ 0.1万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264903
• 关键词: calcium metabolism; chloroquine; clinical research; clinical trial phase I; drug screening /evaluation; human subject; human therapy evaluation; hypercalcemia; hypercalciuria

It is hypothesized that disordered calcium homeostatis in malignant and non-malignant lymphoproliferative disorders may result form the over production of active Vitamin D metabolites in immune cells. The ability of the chloroquine derivatives to inhibit extrarenal 1,25-(OH)2-D production in sarcoidosis, other granuloma-forming states and lymphoma is being assessed. Based upon the patients entered to date, it appears that 1,25-(OH)2-D levels drop significantly within days of treatment initiation.

推测恶性和非恶性淋巴增生性疾病的钙稳态紊乱可能是由于免疫细胞中活性维生素D代谢产物的过度产生所致。氯喹衍生物在结节病、其他肉芽肿形成状态和淋巴瘤中抑制肾外1，25-(OH)2-D产生的能力正在评估中。根据迄今为止输入的患者，1，25-(OH)2-D水平似乎在治疗开始后的几天内显著下降。